Results 1 to 10 of about 119,936 (354)

Protective Effect of Silymarin Against Paclitaxel-Induced Cardiotoxicity. [PDF]

Food Sci Nutr
Tutar T, Yakut S, Kara A, Ulucan A, Çağlayan C.   +4 more
europepmc   +1 more source

Cardiotoxicity Challenges in Nanomaterial: Risk Assessment, Mechanisms, and Mitigation Strategies. [PDF]

Int J Nanomedicine
Li Z, Liu L, Zhang P, Wen Z, Jia Y, Liao X.   +5 more
europepmc   +1 more source

The multifaceted mechanisms of Tanshinone IIA in doxorubicin-induced cardiotoxicity. [PDF]

Front Med (Lausanne)
Wang Q, Zou D, Chen H, Cui D, Huang X, Chen Y, Qi Y, Nan Z, Wang X, Shang X.   +9 more
europepmc   +1 more source

Empagliflozin Mitigates Doxorubicin-Induced Cardiotoxicity in Rats: Electrocardiographic, Biochemical, and Histopathological Evidence. [PDF]

Int J Mol Sci
Goje ID, Ordodi VL, Goje GI, Bojin FM, Crăciun AD, Crîsnic D, Derban M, Barbulescu AS, Ciobotaru VG, Păunescu V, Lighezan DF.   +10 more
europepmc   +1 more source

Cancer Treatment-Related Cardiotoxicity among Survivors of Childhood Cancer: A Comparative and Integrated View of Multiple Measures of Biological Age Acceleration. [PDF]

Cancer Epidemiol Biomarkers Prev
Meng X, Eulalio T, Oh K, Plonski NM, Shelton K, Mulder HL, Easton J, Zhang J, Walker EV, Neale G, Srivastava DK, Howell RM, Mandelblatt JS, Ky B, Dixon SB, Armstrong GT, Hudson MM, Ness KK, Wang Z.   +18 more
europepmc   +1 more source

Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis. [PDF]

Eur Heart J
Zhang K, Ayala A, Norambuena-Soto I, Agnihotri V, Shu T, Nenninger C, Wang Y, Echevarria B, Aboagye J, Huang K, Espitia-Corredor J, Wu X, Chen ZB, Deng Y, Perry JJP, Raz DJ, Yang H, Cheng P, Fu G, Wang ZV, Rhee JW.   +20 more
europepmc   +1 more source

Cardiotoxicity of T cell immunotherapies. [PDF]

Nat Rev Cardiol
Raddatz MA, Stein-Merlob AF, Mahmood SS, Ganatra S, Addison D, Lin TL, Larson SM, Yang EH.   +7 more
europepmc   +1 more source

Treatment of left ventricular dysfunction during cancer therapy: a comprehensive review. [PDF]

Drugs Context
Kaplinsky E, Barbagelata A, Giorgi J, Fischer-Bacca CO.   +3 more
europepmc   +1 more source

Comprehensive toxicity profile of the 4AC-4THP neoadjuvant regimen in HER2-positive breast cancer: a multicenter real-world study in Vietnam. [PDF]

Front Oncol
Tran AD, Trinh LH, Pham TA.
europepmc   +1 more source

Cardiotoxicity [PDF]

, 2020
openaire   +1 more source